3 New Strong Buy Ratings from Top-Rated Analysts: 09/25/2026
Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Warrior Met Coal (HCC) — Premium coal miner with 39% upside target
- QuinStreet (QNST) — Fresh Strong Buy upgrade on 40% ROE
- Bristol-Myers Squibb (BMY) — Our latest Trade of the Week has legs
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
Hoping to Retire Soon?
There's a 73-minute "trading window" that is commonly exploited by retirees and those hoping to retire sooner. It works best if you can make this trade at a very specific time of day.
Click here to know when you should make this morning trade.
1. Warrior Met Coal (NYSE: HCC)
Warrior Met Coal produces premium metallurgical coal for the global steel industry. With a 17.2% profit margin and strengthening coal fundamentals, the company is well-positioned to capitalize on sustained demand from international steelmakers.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $88.47 — get current quote
Max 1-year forecast: $123.00
Why we're watching:
- HCC has limited, but overall bullish, coverage among the analysts we track, with 2 Strong Buy and 1 Hold recommendations. See all recommendations here
- For example, B. Riley Securities researcher Nick Giles (a top 14% rated analyst) maintained his Strong Buy recommendation with a price target suggesting the stock has roughly 40% upside potential from current levels. Giles cited "modestly higher" Blue Creek output assumptions for the price target hike.
- Industry ranking context: HCC is currently the #1 highest-rated stock in the Coking Coal industry, which has an Industry Rating of C.
- Zen Ratings highlights: HCC earns an overall A rating, equal to a Strong Buy recommendation. This tier represents stocks that have historically delivered nearly 30% annual returns, soundly beating the S&P.
- Component Grades: HCC maintains solid Bs for Financials, Growth, and Value, reflecting the company's disciplined capital allocation and stable cash generation. See all 7 Component Grades here
2. QuinStreet (NASDAQ: QNST)
QuinStreet is a global digital performance marketing enterprise specializing in client acquisition solutions and measurable online marketing results. With 40.73% return on equity and 12.2% revenue growth, the company is capturing share in the evolving digital advertising landscape.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $17.26 — get current quote
Max 1-year forecast: $21.00
Why we're watching:
- QNST has limited, but strongly bullish, coverage among the analysts we track, with 1 Strong Buy recommendation. See all recommendations here
- For example, Lake Street researcher Eric Martinuzzi (a top 25% rated analyst) recently upgraded QNST to Strong Buy with a price target suggesting the stock could see over 20% additional upside in the coming year.
- Industry ranking context: QNST is currently the #2 highest-rated stock in the Advertising Agency industry, which has an Industry Rating of D.
- Zen Ratings highlights: QNST receives an overall A rating, which amounts to a Strong Buy recommendation. Stocks with this rating represent the elite top 5% of all 4,600+ stocks tracked based on a rigorous 115-factor fundamental review.
- Component Grades: QNST excels for Growth with an A grade, reflecting impressive earnings expansion of 17.17%, while maintaining a strong B for Financials driven by exceptional return on equity. See all 7 Component Grades here
3. Bristol Myers Squibb (NYSE: BMY)
One of the world’s largest pharma companies just earned our Editor-in-Chief’s Trade of the Week designation. With an 18.9% profit margin, a 45.1% return on equity, and fresh late-stage pipeline wins, the company is executing a portfolio renewal that analysts are increasingly willing to underwrite.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $62.25 — get current quote
Max 1-year forecast: $82.00
Why we're watching:
- BMY has broad, bullish coverage among the analysts we track, with 7 Strong Buy and 5 Hold recommendations. See all recommendations here
- For example, Piper Sandler researcher David Amsellem (a top 4% rated analyst) recently reiterated his Strong Buy recommendation with a price target suggesting the stock could see greater than 30% upside in the coming year.
- Our own Editor-in-Chief, Steve Reitmeister, is even more bullish on the stock. He named it as his Trade of the Week in our most recent WallStreetZen Live webinar … If you want to get our next pick before the crowd, join our next no-paywall event this coming Monday. Sign up here.
- Pipeline catalyst: BMY announced positive topline results from a Phase 2 trial, with the program meeting its main goal in mid-stage testing.
- Industry ranking context: BMY is currently the #1 highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A.
- Zen Ratings highlights: BMY earns an overall A rating, which is equal to a Strong Buy recommendation. Stocks in this topmost tier have historically delivered nearly 30% annual returns, soundly beating the S&P.
- Component Grades: BMY excels for Value and Sentiment with A grades, reflecting a P/E of under 14 against an industry average near 40 alongside strengthening analyst conviction, while maintaining solid Bs for Momentum, Safety, Financials, and Artificial Intelligence — a six-grade strength profile that positions it as one of the better-rounded large-cap pharma setups available. See all 7 Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.